Geographic Atrophy Secondary to Age-related Macular Degeneration
Ophthalmology·MeSH: Macular Degeneration
Prevalence
2000.0 / 100K
Incidence
200.0 / 100K/yr
6 drugs in development·4 companies·6 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| SYFOVRE | Apellis Pharmaceuticals, Inc. (APLS) |
Phase 3(1)
Compare drugs
Frequently asked questions
How many drugs are in development for Geographic Atrophy Secondary to Age-related Macular Degeneration?
BioSniper tracks 6 drugs in development for Geographic Atrophy Secondary to Age-related Macular Degeneration across 4 companies.
How many clinical trials target Geographic Atrophy Secondary to Age-related Macular Degeneration?
There are 6 clinical trials targeting Geographic Atrophy Secondary to Age-related Macular Degeneration tracked by BioSniper.
What is the prevalence of Geographic Atrophy Secondary to Age-related Macular Degeneration?
The estimated prevalence of Geographic Atrophy Secondary to Age-related Macular Degeneration is approximately 2000.0 per 100,000 population.
Deep-dive into Geographic Atrophy Secondary to Age-related Macular Degeneration
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis